Bebetter Med Inc.

Dongguan Zhenxing-Beite Medicine Technology Co., Ltd.

Dongguan Zhengxing-Beite Medicine Technology Co., Ltd.

Qijie He

Xiong Cai

Changgeng Qian

Chunqiang Ye

Shifeng Qin

Xianbin Zhong

Provided are a 1,3-di-substituted ketene compound having a structure as represented by formula (I) and an application thereof. Such a type of compound primarily activates peroxisome proliferator-activated receptor (PPAR) &#x3b1;, and also activates PPPA&#x3b4; and PPPA&#x3b3;. The compound may be used to treat various diseases associated with PPAR regulation and control abnormality, such as non-alcoholic fatty liver disease, and especially in treating non-alcoholic hepatitis, and may potentially be used in the treatment of diseases comprising diabetes, obesity, fibrotic diseases, cardiovascular diseases (comprising heart failure, atherosclerosis, and so on), kidney diseases (comprising chronic kidney disease, renal failure, and so on), and brain degenerative diseases (comprising Alzheimer's disease and so on), having great application value. 

1,3-di-substituted ketene compound and application thereof

Disclosed are an imidazopyrazine compound, a preparation method therefor and use thereof. Specifically, disclosed are a compound having a structure as represented by formula (I), a pharmaceutically acceptable salt, a stereoisomer or a prodrug thereof, and use of the compound, the pharmaceutically acceptable salt, the stereoisomer or the prodrug thereof in the preparation of a medicament. The medicament is used for preventing and/or treating diseases and/or conditions related to Bruton's tyrosine kinase overactivity in a subject. Further disclosed is use of the compound, the pharmaceutically acceptable salt, the stereoisomer or the prodrug thereof in the preparation of a formulation. The formulation is used for reducing or inhibiting the activity of the Bruton's tyrosine kinase in cells. 

Imidazopyrazine compounds, preparation methods and uses thereof

Growing community of inventors

Dongguan, China

Qijie He